Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
Journal of Antimicrobial Chemotherapy · 02.02.2026 · 81 (3)
DOI: 10.1093/jac/dkag054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.02.2026. Verfasst von Daisuke Fukuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines and Infectious Diseases, GSK, Tokyo, Japan. Hauptthemen laut MEDLINE: DNA Topoisomerase IV, Anti-Bacterial Agents, Quinolones, Topoisomerase II Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Bacterial topoisomerases are enzymes critical for maintaining genomic DNA integrity and ensuring bacterial cell survival, making them ideal targets for antibacterial agents. Bacterial topoisomerase inhibitors, such as quinolones and fluoroquinolones, target two enzymes, DNA gyrase and topoisomerase IV, and inhibit the control of DNA supercoiling/decatenation, leading to impaired DNA replication and bacterial cell death. Since their initial discovery, many quinolones and fluoroquinolones have been developed with activity against a wide range of bacterial species, contributing significantly to the treatment of various infectious diseases worldwide. Fluoroquinolones such as levofloxacin and ciprofloxacin remain important and effective therapeutic options today due to their broad-spectrum antibacterial activity, chemical stability and high bioavailability. However, side effects of fluoroquinolones have become a concern, leading to warnings being issued in the United States, Europe and the United Kingdom. Furthermore, in many countries, the prevalence of fluoroquinolone-resistant bacteria has been steadily increasing each year, which poses a serious threat to public health. The clinical development of new non-quinolone bacterial topoisomerase inhibitors (for example, zoliflodacin, gepotidacin and fobrepodacin) offers a promising solution to these issues and has the potential to play a crucial role in combating the growing problem of antimicrobial resistance. This review article will discuss the evolution of quinolone and fluoroquinolone antibacterial agents as key topoisomerase inhibitors, examine their current clinical applications and challenges to future development, and explore the potential of new topoisomerase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccines and Infectious Diseases, GSK, Tokyo, Japan.
- Antibiotics, GSK, London, UK.
- Value Evidence and Outcomes, Specialty Care, GSK, Tokyo, Japan.
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
ORCID-Profile: Satowa Suzuki
Förderung
- GSK
Zitieren
APA
Fukuda, D., Powell, D., Mulgirigama, A., Vojtek, I., Ozeki, H., Yoshimoto, D., Iida, H., Johira, N., Kayama, Y., Kawamatsu, S., & Suzuki, S. (2026). Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future. Journal of Antimicrobial Chemotherapy, 81(3). https://doi.org/10.1093/jac/dkag054
Vancouver
Fukuda D, Powell D, Mulgirigama A, Vojtek I, Ozeki H, Yoshimoto D, et al. Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future. Journal of Antimicrobial Chemotherapy. 2026;81(3). doi:10.1093/jac/dkag054
BibTeX
@article{Fukuda2026,
author = {Fukuda, Daisuke and Powell, Danielle and Mulgirigama, Aruni and Vojtek, Ivo and Ozeki, Hirofumi and Yoshimoto, Daisuke and Iida, Hideki and Johira, Naoki and Kayama, Yoko and Kawamatsu, Shinya and Suzuki, Satowa},
title = {Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {3},
doi = {10.1093/jac/dkag054}
}
EUVIMED